The secondary mutation of KRAS and acquired resistance to anti-EGFR therapy in metastatic colorectal cancer

被引：0
|
作者：
Xia, X.
Du, W.
Zhu, Y.
Bai, Y.
Liu, M.
机构：
来源：
CLINICAL & EXPERIMENTAL METASTASIS | 2017年 / 34卷 / 3-4期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
下载
收藏
页码：218 / 218
页数：1
相关论文
共 50 条
  • [1] Emergence of KRAS mutations and acquired resistance to anti-EGFR therapy in colorectal cancer
    Sandra Misale
    Rona Yaeger
    Sebastijan Hobor
    Elisa Scala
    Manickam Janakiraman
    David Liska
    Emanuele Valtorta
    Roberta Schiavo
    Michela Buscarino
    Giulia Siravegna
    Katia Bencardino
    Andrea Cercek
    Chin-Tung Chen
    Silvio Veronese
    Carlo Zanon
    Andrea Sartore-Bianchi
    Marcello Gambacorta
    Margherita Gallicchio
    Efsevia Vakiani
    Valentina Boscaro
    Enzo Medico
    Martin Weiser
    Salvatore Siena
    Federica Di Nicolantonio
    David Solit
    Alberto Bardelli
    Nature, 2012, 486 : 532 - 536
  • [2] Emergence of KRAS mutations and acquired resistance to anti-EGFR therapy in colorectal cancer
    Misale, Sandra
    Yaeger, Rona
    Hobor, Sebastijan
    Scala, Elisa
    Janakiraman, Manickam
    Liska, David
    Valtorta, Emanuele
    Schiavo, Roberta
    Buscarino, Michela
    Siravegna, Giulia
    Bencardino, Katia
    Cercek, Andrea
    Chen, Chin-Tung
    Veronese, Silvio
    Zanon, Carlo
    Sartore-Bianchi, Andrea
    Gambacorta, Marcello
    Gallicchio, Margherita
    Vakiani, Efsevia
    Boscaro, Valentina
    Medico, Enzo
    Weiser, Martin
    Siena, Salvatore
    Di Nicolantonio, Federica
    Solit, David
    Bardelli, Alberto
    NATURE, 2012, 486 (7404) : 532 - U131
  • [3] Drivers of secondary resistance to anti-EGFR therapy in metastatic colorectal cancer
    Noseir, Soha Hussein
    Hahn, Stephan
    Maghnouj, Abdelouahid
    Ladigan, Swetlana
    CANCER RESEARCH, 2020, 80 (16)
  • [4] Drivers of Secondary Resistance to Anti-Egfr Therapy in Metastatic Colorectal Cancer
    Noseir, Soha
    Hahn, Stephan
    Maghnouj, Abdelonahid
    Ladigan, Swetlana
    ONCOLOGY RESEARCH AND TREATMENT, 2020, 43 : 219 - 219
  • [5] Overcoming the Hurdles: Surmounting Acquired Resistance to Anti-EGFR Therapy in Metastatic Colorectal Cancer
    Sackstein, Paul E.
    Chintapally, Nikita
    Wilgucki, Molly
    Hartley, Marion L.
    Alqahtani, Ali
    Weinberg, Benjamin A.
    CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY, 2023, 21 (11) : 572 - 583
  • [6] KRAS mutation testing in the treatment of metastatic colorectal cancer with anti-EGFR therapies
    Soulieres, D.
    Greer, W.
    Magliocco, Anthony M.
    Huntsman, D.
    Young, S.
    Tsao, M-S.
    Kamel-Reid, S.
    CURRENT ONCOLOGY, 2010, 17 : S31 - S40
  • [7] Concordance of KRAS/BRAF Mutation Status in Metastatic Colorectal Cancer before and after Anti-EGFR Therapy
    Gattenloehner, S.
    Etschmann, B.
    Kunzmann, V.
    Thalheimer, A.
    Hack, M.
    Kleber, G.
    Einsele, H.
    Germer, C.
    Mueller-Hermelink, H. -K.
    JOURNAL OF ONCOLOGY, 2009, 2009
  • [8] Beyond KRAS status and response to anti-EGFR therapy in metastatic colorectal cancer
    Perkins, Geraldine
    Pilati, Camilla
    Blons, Helene
    Laurent-Puig, Pierre
    PHARMACOGENOMICS, 2014, 15 (07) : 1043 - 1052
  • [9] KRAS Mutation Testing of Colorectal Cancer for Anti-EGFR Therapy: Dogmas Versus Evidence
    Timar, J.
    Hegedus, B.
    Raso, E.
    CURRENT CANCER DRUG TARGETS, 2010, 10 (08) : 813 - 823
  • [10] Clinical interest of KRAS mutation detection in blood for anti-EGFR therapies in metastatic colorectal cancer
    F Di Fiore
    F Charbonnier
    B Lefebure
    M Laurent
    F Le Pessot
    P Michel
    T Frebourg
    British Journal of Cancer, 2008, 99 : 551 - 552
12345